Novartis is planning to boost its cancer immunotherapy pipeline with a collaboration with California-based Aduro Biotech worth up to $750 million.
The partnership is focused on the development of cancer immunotherapies based on Aduro’s STING (Stimulator of Interferon Genes) technology, a next-generation method to harness the body’s immune system to fight cancer.
Read more